Related references
Note: Only part of the references are listed.Significantly Improving the Prediction of Molecular Atomization Energies by an Ensemble of Machine Learning Algorithms and Rescanning Input Space: A Stacked Generalization Approach
Ruobing Wang
JOURNAL OF PHYSICAL CHEMISTRY C (2018)
Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty The GIFT Randomized Clinical Trial
Brian F. Gage et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database
Rong Liu et al.
PLOS ONE (2015)
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy
Kaitlyn Shaw et al.
THERAPEUTIC DRUG MONITORING (2015)
Improvement of Adequate Use of Warfarin for the Elderly Using Decision Tree-based Approaches
K. E. Liu et al.
METHODS OF INFORMATION IN MEDICINE (2014)
Prediction of optimal warfarin maintenance dose using advanced artificial neural networks
Enzo Grossi et al.
PHARMACOGENOMICS (2014)
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Predicting warfarin dosage from clinical data: A supervised learning approach
Ya-Han Hu et al.
ARTIFICIAL INTELLIGENCE IN MEDICINE (2012)
A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
Jeffrey L. Anderson et al.
CIRCULATION (2012)
Warfarin Pharmacogenetics A Rising Tide for Its Clinical Value
Julie A. Johnson
CIRCULATION (2012)
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Nita A. Limdi et al.
BLOOD (2010)
Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing
P. Lenzini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Warfarin pharmacogenetics:: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
Stuart A. Scott et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
B. F. Gage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Using stacked generalization to predict membrane protein types based on pseudo-amino acid composition
Shuang-Quan Wang et al.
JOURNAL OF THEORETICAL BIOLOGY (2006)
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status:: Interaction between both genotypes affects overanticoagulation
Tom Schalekamp et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
G D'Andrea et al.
BLOOD (2005)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
S Rost et al.
NATURE (2004)
Share Paper
